Intra-Cellular Therapies Inc. (ITCI)

NASDAQ: ITCI · IEX Real-Time Price · USD
59.25
0.33 (0.56%)
May 17, 2022 3:48 PM EDT - Market open
Market Cap5.59B
Revenue (ttm)102.92M
Net Income (ttm)-303.50M
Shares Out94.32M
EPS (ttm)-3.50
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume576,407
Open59.92
Previous Close58.92
Day's Range58.59 - 60.11
52-Week Range28.40 - 66.00
Beta1.19
AnalystsBuy
Price Target72.32 (+22.1%)
Earnings DateMay 10, 2022

About ITCI

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as s...

IndustryPharmaceuticals
CEOSharon Mates
Employees512
Stock ExchangeNASDAQ
Ticker SymbolITCI
Full Company Profile

Financial Performance

In 2021, ITCI's revenue was $83.80 million, an increase of 267.35% compared to the previous year's $22.81 million. Losses were -$284.13 million, 25.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for ITCI stock is "Buy." The 12-month stock price forecast is 72.32, which is an increase of 22.06% from the latest price.

Price Target
$72.32
(22.06% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Intra-Cellular Therapies Stock Rose 21.4% This Week

Strong sales for the company's only marketed therapy piqued investors' interest.

4 days ago - The Motley Fool

Why Intra-Cellular Therapies Trounced the S&P 500 Today

The biotech notches an extremely convincing first-quarter earnings beat.

6 days ago - The Motley Fool

Robust Uptake Of Antipsychotic Drug Boosts Intra-Cellular's Q1 Earnings

Intra-Cellular Therapies Inc's (NASDAQ: ITCI) Q1 revenues reached $35.0 million, compared to $15.9 million a year ago, beating the consensus of $33.65 million. Net product revenues of Caplyta were $34.8...

1 week ago - Benzinga

Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 16.13% and 5.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

First quarter 2022 results reflect strong CAPLYTA ® (lumateperone) launch in bipolar depression

1 week ago - GlobeNewsWire

Analysts Estimate Intra-Cellular Therapies (ITCI) to Report a Decline in Earnings: What to Look Out for

Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 0% and 3.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Received FDA approval for CAPLYTA ® (lumateperone) for the treatment of bipolar depression in adults.

2 months ago - GlobeNewsWire

Why Earnings Season Could Be Great for Intra-Cellular Therapies (ITCI)

Intra-Cellular Therapies (ITCI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast

NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervou...

2 months ago - GlobeNewsWire

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Intra-Cellular Therapies to Present at the 11th Annual SVB Leerink Global Healthcare Conference

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervou...

3 months ago - GlobeNewsWire

12 biotech stocks to consider buying now as prospects for the sector brighten this year

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

3 months ago - Market Watch

Strength Seen in Intra-Cellular (ITCI): Can Its 9.8% Jump Turn into More Strength?

Intra-Cellular (ITCI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down th...

3 months ago - Zacks Investment Research

Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' O...

NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervou...

4 months ago - GlobeNewsWire

Intra-Cellular Therapies Prices Public Offering of Common Stock

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervou...

4 months ago - GlobeNewsWire

Why Intra-Cellular Therapies Took a Big Hit Today

The company is floating at least $400 million worth of its common stock.

4 months ago - The Motley Fool

IntraCellular Seeks To Raise $400M Via Equity To Fund Commercialization Of Schizophrenia Med

Intra-Cellular Therapies Inc (NASDAQ: ITCI) commenced an underwritten public offering of $400 million of shares. Underwriters have an option to purchase up to an additional 15% of the shares of common s...

4 months ago - Benzinga

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervou...

4 months ago - GlobeNewsWire

FDA Approves Intra-Cellular's Antipsychotic For Bipolar Depression

The FDA has approved Intra-Cellular Therapies Inc (NASDAQ: ITCI) Caplyta for depressive episodes associated with bipolar I or II disorder in adults. The approval for Caplyta comes as monotherapy and as ...

4 months ago - Benzinga

Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depressi...

CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valpro...

4 months ago - GlobeNewsWire

Intra-Cellular Therapies Mourns the Passing of Director, Dr. Richard Lerner

NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous...

5 months ago - GlobeNewsWire

Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of -6.74% and 1.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Intra-Cellular Therapies: Q3 Earnings Insights

Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

6 months ago - Benzinga

Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update

CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021.

6 months ago - GlobeNewsWire